Inhaled Epoprostenol for Pulmonary Hypertension Treatment in Neonates: A 12-Year Experience.

There is no author summary for this article yet. Authors can add summaries to their articles on ScienceOpen to make them more accessible to a non-specialist audience.

Abstract

Persistent pulmonary hypertension of the newborn (PPHN) occurs in 10% of neonatal respiratory insufficiency. To selectively reduce pulmonary vascular resistance, several treatments have been tried. Inhaled epoprostenol (iPGI2) has been used for 12 years in our institution for the management of refractory PPHN despite the gaps in the literature to support this use.

Related collections

Author and article information

Journal

Journal ID (iso-abbrev): Am J Perinatol

Title: American journal of perinatology

Publisher: Georg Thieme Verlag KG

ISSN (Electronic): 1098-8785

ISSN (Print): 0735-1631

Publication date (Electronic): September 2019

Volume: 36

Issue: 11

Affiliations

[1 ] Department of Paediatrics, CHU de Québec, Université Laval, Québec City, Québec, Canada.

[2 ] Division of Neonatology, Department of Paediatrics, CHU de Québec, Université Laval, Québec City, Québec, Canada.

[3 ] Division of Pediatric Intensive Care, Department of Paediatrics, CHU de Québec, Université Laval, Québec City, Québec, Canada.

[4 ] Department of Biostatistic, Centre de recherche du CHUQ, Université Laval, Québec City, Québec, Canada.

[5 ] Division of Pediatric Cardiology, Department of Paediatrics, CHU de Québec, Québec City, Québec, Canada.

[6 ] Department of Pharmacy, CHU de Québec, Université Laval, Québec City, Québec, Canada.

Article

DOI: 10.1055/s-0038-1676483

PubMed ID: 30551229

SO-VID: 90acdf04-ab52-43bc-ab45-33b625cd83cd

History

Data availability:

Comments

Comment on this article

scite_

Cited by 2

See all cited by